Floatz logo

Rituximab

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
65/ 100

Competitive context

202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Prednisone
AstraZeneca
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

Rituximab is also rated in:

lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
grade III lymphomatoid granulomatosisDormant
BBB
Indicative · Phase 2
74 / 100
View asset →
testicular lymphomaDormant
BBB
Indicative · Phase 2
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →